HANGZHOU Solution in Bicuspid AS Undergoing TAVR
A legfontosabb adatok
- Ki végzi
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Hol
- Kína18 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 508 fő, tervezett
- Kezdés
- 2021. ápr. 12.
- Várható befejezés
- 2028. ápr. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
- TAVR with Venus A plus using annular sizing and THV implantation technique
- A regiszteradat frissítve
- 2021. június 2.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people with severe narrowing of a bicuspid aortic valve (a heart valve with two flaps instead of three). They will have a valve replaced through a tube in the groin artery (transfemoral TAVR). The trial compares two ways of choosing the valve size.
- Életkor
- 65 years or older. People aged 60 to under 65 years can join if their risk from open-heart surgery is high.
- Nem
- All sexes
- A betegség stádiuma
- Severe bicuspid aortic stenosis: mean gradient ≥40 mmHg, maximal aortic valve velocity ≥4.0 m/sec, aortic valve area ≤1.0 cm2 (or aortic valve area index ≤0.6 cm2/m2). NYHA class II or higher (symptoms with activity). Sievers type 0 or type 1 on MDCT scan. Valve ring (annulus) diameter 20.0 mm to 29.0 mm.
- Korábbi kezelés
- People with a pacemaker already fitted cannot join.
A részvétel fő kizáró okai
- Heart attack within 1 month (30 days), or stroke or mini-stroke (TIA) within 3 months (90 days)
- Active serious infection, including infection of the heart valves
- Expected to live less than 12 months (365 days) due to cancer or chronic liver, kidney or lung disease
- Low blood counts: WBC < 3000 cell/mL, Hgb < 9 g/dL, or Plt< 50,000 cell/mL
- Ascending aorta wider than 50 mm, or blood vessels that make the procedure unsafe
A regiszter feltételei, szó szerint
Mind a 33 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 65 years
- Age <65 years and age ≥ 60 years with high surgical risk after combing STS Risk Estimate, Katz activities of Daily Living, major Organ System Dysfunction and Procedure-Specific Impediment
- Severe, bicuspid aortic stenosis:
- Mean gradient ≥40 mmHg
- Maximal aortic valve velocity ≥4.0 m/sec
- Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2)
- NYHA classification ≥ II
- Type 0, type 1 (Sievers classification) by MDCT
- Perimeter-derived annulus diameter ranges from 20.0 mm to 29.0 mm
- Transfemoral TAVR
- The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site
Ki nem vehet részt
- Any Emergent surgery required before TAVR procedure
- Currently participating in an investigational drug or another device study (excluding registries)
- Severe mitral stenosis amenable to surgical replacement or repair
- Previous pacemaker implantation
- Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment [(defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)]
- Stroke or transient ischemic attack (TIA) within 3 months (90 days) of the procedure
- Estimated life expectancy < 12 months (365 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease
- A known hypersensitivity or contraindication to any of the following that cannot be adequately medicated:aspirin or heparin (HIT/HITTS) and bivalirudin, clopidogrel,Nitinol (titanium or nickel),contrast media
- Gastrointestinal (GI) bleeding that would preclude anticoagulation
- Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
- Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams
- Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe"unfolding" and horizontal aorta(Annular Angulation>70°)
- Leukopenia (WBC < 3000 cell/mL), acute anemia (Hgb < 9 g/dL), Thrombocytopenia (Plt< 50,000 cell/mL)
- Any contra-indication for Self-expanding bioprosthetic aortic valve deployment
- Active sepsis, including active bacterial endocarditis with or without treatment
- Subject refuses a blood transfusion
- Hypertrophic cardiomyopathy (HCM with myocardium more than 1.5cm without an identifiable cause) with obstruction (HOCM)
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- Aortic valve type cannot be determined (Sievers classification)
- Ascending aorta diameter > 50 mm
- Aortic or iliofemoral vessel characteristics that would preclude safe placement of the introducer sheath
- Patient is considered high risk for TAVR by CT corelab, including coronary obstruction, annular rupture and other severe TAVR-Related complications
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To compare supra-annular sizing and THV implantation technique (Hangzhou solution) versus annular sizing and THV implantation technique (control group) in bicuspid aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR) with self-expanding valves (SEVs): a randomized superiority trial
A vizsgálat 2 csoportja
- TAVR with Supra-annular sizing strategyA vizsgált kezelés
Experimental: Supra-annular sizing strategy (Hangzhou Solution). Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size. Waist sign with less than mild contrast regurgitation: Venus A plus Valve down size and Target implant depth 0-2mm. No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: annular sizing Venus A plus Valve with implant depth 4-6mm.
Kezelés: TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
- TAVR with Annulus based sizing strategyEgyéb csoport
Control: Traditional sizing strategy (Annulus based sizing strategy). Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size. Annular sizing Venus A plus Valve with implant depth 4-6mm.
Kezelés: TAVR with Venus A plus using annular sizing and THV implantation technique
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- HANGZHOU Solution for Patients With Bicuspid Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement by Using Supra-annular Structure Based Balloon Sizing Strategy
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2021. június 2.